Lexicon Pharma (LXRX) Tops Q1 EPS by 9c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.05 +0.49%
Revenue Growth %: -78.9%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: -78.9%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q1 EPS of ($0.33), $0.09 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $18.3 million versus the consensus estimate of $17.71 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
